Enanta Pharmaceuticals, Inc.
ENTANext catalyst
zelicapavir
RSV Infection
Get an email about ENTA's next catalysts
Track Enanta Pharmaceuticals (ENTA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ENTA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.82 | FQ end Sep/2026 | Call: tbd
zelicapavir Phase 2 Est. Readout
Estimated primary completion for zelicapavir trial (NCT07482657) in RSV Infection. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
EDP-938
Respiratory Syncytial Virus
EDP-938 Dose 1
RSV Infection
EDP-235
COVID-19
EDP-305
Primary Biliary Cholangitis
EDP-305 Dose 1
Non-Alcoholic Steatohepatitis
EDP-323 Dose Regimen 1
RSV Infection
zelicapavir
RSV Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EDP-938 | Phase 2 | Respiratory Syncytial Virus | - | - |
EDP-938 Dose 1 | Phase 2 | RSV Infection | - | - |
EDP-235 | Phase 2 | COVID-19 | - | - |
EDP-305 | Phase 2 | Primary Biliary Cholangitis | - | - |
EDP-305 Dose 1 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
EDP-323 Dose Regimen 1 | Phase 2 | RSV Infection | - | - |
zelicapavir | Phase 2 | RSV Infection | - | - |
RSV Infection
2 drugs in this indication
Primary Biliary Cholangitis
2 drugs in this indication
Respiratory Syncytial Virus
1 drug in this indication
COVID-19
1 drug in this indication
Non-Alcoholic Steatohepatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Enanta Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Enanta Pharmaceuticals, Inc.'s (ENTA) pipeline across Phase 2. Its lead program is zelicapavir (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Enanta Pharmaceuticals, Inc.'s next FDA catalyst?→
Enanta Pharmaceuticals, Inc.'s (ENTA) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENTA biotech catalysts?→
Add ENTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Enanta Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.